{"name":"Yang Jianjun, PhD","slug":"yang-jianjun-phd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Adebrelimab combined with SOX regimen","genericName":"Adebrelimab combined with SOX regimen","slug":"adebrelimab-combined-with-sox-regimen","indication":"Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy)","status":"marketed"},{"name":"nab-paclitaxel，Cisplatin","genericName":"nab-paclitaxel，Cisplatin","slug":"nab-paclitaxel-cisplatin","indication":"Non-small cell lung cancer","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"nab-paclitaxel, lobaplatin, and S-1","genericName":"nab-paclitaxel, lobaplatin, and S-1","slug":"nab-paclitaxel-lobaplatin-and-s-1","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Adebrelimab combined with SOX regimen","genericName":"Adebrelimab combined with SOX regimen","slug":"adebrelimab-combined-with-sox-regimen","phase":"marketed","mechanism":"Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.","indications":["Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy)"],"catalyst":""},{"name":"nab-paclitaxel, lobaplatin, and S-1","genericName":"nab-paclitaxel, lobaplatin, and S-1","slug":"nab-paclitaxel-lobaplatin-and-s-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"nab-paclitaxel，Cisplatin","genericName":"nab-paclitaxel，Cisplatin","slug":"nab-paclitaxel-cisplatin","phase":"marketed","mechanism":"nab-paclitaxel and cisplatin work together as a chemotherapy combination to disrupt microtubule dynamics and cause DNA cross-linking, respectively, leading to cancer cell death.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}